CORE FACILITY PROFILE
Core Facility: Center for Regenerative Medicine iPSC Core
Institutes: Boston University and Boston Medical Center
Location: Boston, MA, USA
The Center for Regenerative Medicine (CReM) iPSC Core at Boston University and Boston Medical Center was created in 2014 to expedite the use of iPSC technology by providing essential services and support to on-campus investigators and the broader scientific community.
The CReM iPSC Core maintains both control and disease-specific iPSCs, numerous isogenic gene-edited iPSCs, and recently has become the sole iPSC repository for the Framingham Heart Study (FHS). To support work involving iPSCs, the CreM facility provides consultation, on-line protocols, and hands-on training classes. The iPSC Core is primarily funded by the NIH while additional financial support is provided by operating costs, contracts and industry fees. Reprogramming, characterization, expansion, and on-site banking are offered to external investigators on a fee for service or collaborative basis. The CReM iPSC Core reprograms approximately 30 samples per year.
The training course in basic iPS cell culture techniques is offered year-round, and an intensive, week-long course in iPSC directed-differentiation to endoderm and lung progeny is offered annually. This advanced course is attended by local, national and international lung researchers and clinicians.
To further its goal, the CReM iPSC Core distributes all available iPS cells generated and/or banked by the core to the academic research community in accordance with the CReM’s “Open Source Biology” approach.
The director of the CreM iPSC Core is Gustavo Mostoslavsky, MD, PhD, and the facility is managed by Marianne James. Other core facility members include Aine Russell (lab technician) and Jean Jyh-Chang, PhD (part-time) (instructor).
The Lung Regeneration Initiative and iPS Cell Core facility was made possible by a Massachusetts Life Sciences Center (MLSC) award (PI: Dr. Darrell Kotton) (credit: BU)
The CReM iPSC Core of Boston University and Boston Medical Center (credit: BU)
Characterization of iPSC lines: a patient bronchial epithelial cell sample was reprogrammed to iPS cells and stained for pluripotency markers, Tra-1-60, Tra-1-81, SSEA-1 and SSEA-4 by immunofluorescence methods (credit: BU)
Screenshot of the online CReM iPSC Core Repository describing iPS cell lines available for distribution via stemcellbank.bu.edu/catalog/item/home (credit: BU)
Profile submitted by: Marianne James
Page last updated: October 31, 2019